The role of marine n-3 fatty acids in improving cardiovascular health: a review

Abstract

Omega 3 polyunsaturated fatty acids (n-3 PUFA) have long been studied for their health benefits. In particular, marine n-3 PUFA such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been shown to possess cardiovascular protective qualities. However, there is conflicting evidence as to the mechanisms, effectiveness and doses required to observe these benefits. The objective of this review is to provide existing evidence as to the role of marine n-3 PUFA on cardiovascular health, as well as provide novel aspects to the current literature as of September 2012. Three large randomized clinical studies were reviewed to determine if there was an inverse association between n-3 fatty acid intake and CVD. There is strong evidence that the pharmaceutical grade n-3 fatty acid drug Lovaza™, (previously Omacor™) is effective in reducing triglyceride levels in humans. However, there are possible adverse reactions that need to be taken into account and caution should be used in treating certain populations. The Omega-3 Index is a promising novel biomarker for assessing long term EPA + DHA status in humans. Due to the originality of the Index, additional evidence is required to assess this as a tool for predicting CVD. Future research is needed to determine the individual effects of EPA and DHA for cardio-protection.